Targeted News Service

Johnson & Johnson Submits Application to the European Medicines Agency Seeking Indication Extension of AKEEGA for the Treatment of Adult Patients With Metastatic Hormone-Sensitive Prostate Cancer and HRR Gene Alterations
July 04, 2025

RARITAN, New Jersey, July 4 -- Johnson and Johnson Innovative Medicine (formerly the Janssen Pharmaceutical Companies of Johnson and Johnson) issued the following news release:

* * *

Johnson & Johnson submits application to the European Medicines Agency seeking indication extension of AKEEGA (niraparib and abiraterone acetate dual action tablet) for the treatment of adult patients with metastatic hormone-sensitive prostate cancer and HRR gene alterations

Targeted News Service Document Request Form

This document is available to you by e-mail if you complete the form below with relevant information. There may be a fee for this article or ongoing service of similar materials. We will be in touch shortly.

Name:
What's your Affiliation	Government Newspaper / Media Business Public Policy Individual / Student Educators
Email:
Phone:
Organization, if any:
State/Country you are in:
Additonal questions or comments:

Click here for more information about our products

Existing Customer Login

Targeted News Service Document Request Form